Gilead Sciences (GILD) Earns Buy Rating from Evercore ISI

Gilead Sciences (NASDAQ:GILD)‘s stock had its “buy” rating reiterated by Evercore ISI in a note issued to investors on Friday, TipRanks reports.

Other analysts also recently issued research reports about the company. Wells Fargo & Co downgraded Gilead Sciences from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $95.00 to $68.00 in a research note on Monday, February 11th. Zacks Investment Research upgraded Gilead Sciences from a “sell” rating to a “hold” rating in a research note on Tuesday, April 9th. UBS Group upgraded Gilead Sciences from a “neutral” rating to a “buy” rating and increased their target price for the company from $75.00 to $77.00 in a research note on Wednesday, April 10th. BidaskClub upgraded Gilead Sciences from a “sell” rating to a “hold” rating in a research note on Friday, May 3rd. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research note on Monday, May 6th. Nine equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. Gilead Sciences presently has a consensus rating of “Buy” and a consensus price target of $81.61.

Shares of Gilead Sciences stock traded up $0.58 during midday trading on Friday, hitting $66.36. The company had a trading volume of 5,922,988 shares, compared to its average volume of 7,334,711. The company has a quick ratio of 3.53, a current ratio of 3.62 and a debt-to-equity ratio of 1.09. The company has a market capitalization of $83.25 billion, a P/E ratio of 10.79, a PEG ratio of 0.79 and a beta of 1.14. Gilead Sciences has a 52-week low of $60.32 and a 52-week high of $79.61.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported $1.76 earnings per share for the quarter, topping the consensus estimate of $1.53 by $0.23. The company had revenue of $5.28 billion for the quarter, compared to the consensus estimate of $5.29 billion. Gilead Sciences had a return on equity of 37.98% and a net margin of 26.40%. The firm’s quarterly revenue was up 3.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.48 EPS. As a group, equities analysts expect that Gilead Sciences will post 6.6 EPS for the current year.

In other news, Director Richard James Whitley sold 9,534 shares of the firm’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $65.48, for a total value of $624,286.32. Following the transaction, the director now directly owns 34,669 shares in the company, valued at approximately $2,270,126.12. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director John Francis Cogan sold 2,868 shares of the firm’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $64.89, for a total value of $186,104.52. Following the completion of the transaction, the director now owns 57,728 shares in the company, valued at $3,745,969.92. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 47,670 shares of company stock worth $3,142,526. Company insiders own 0.20% of the company’s stock.

Institutional investors have recently made changes to their positions in the stock. Gradient Investments LLC raised its holdings in Gilead Sciences by 16.1% during the fourth quarter. Gradient Investments LLC now owns 1,076 shares of the biopharmaceutical company’s stock valued at $67,000 after acquiring an additional 149 shares during the period. Lenox Wealth Management Inc. raised its holdings in Gilead Sciences by 1.8% during the first quarter. Lenox Wealth Management Inc. now owns 9,059 shares of the biopharmaceutical company’s stock valued at $589,000 after acquiring an additional 156 shares during the period. Vectors Research Management LLC raised its holdings in Gilead Sciences by 6.3% during the fourth quarter. Vectors Research Management LLC now owns 2,651 shares of the biopharmaceutical company’s stock valued at $166,000 after acquiring an additional 157 shares during the period. Creative Financial Designs Inc. ADV raised its holdings in Gilead Sciences by 55.9% during the first quarter. Creative Financial Designs Inc. ADV now owns 460 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 165 shares during the period. Finally, Rathbone Brothers plc raised its holdings in Gilead Sciences by 3.1% during the first quarter. Rathbone Brothers plc now owns 5,547 shares of the biopharmaceutical company’s stock valued at $361,000 after acquiring an additional 167 shares during the period. 79.94% of the stock is currently owned by institutional investors.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

See Also: What is a balanced fund?

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.